Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~* Are at least 12 years of age and no older than 65 years~* Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis~* Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy~* Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society \[ATS\]/European Respiratory Society \[ERS\] acceptability/repeatability criteria~* Pre-bronchodilator FEV1 of ≥40 to \<90% predicted normal value after withholding SABA for ≥6 hours~* Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1 of ≥15%~* only 2 reversibility testing attempts are allowed~Exclusion Criteria:~* Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)~* Oral corticosteroid use (any dose) within 6 weeks~* Current smokers, former smokers with \>10 pack-years history, or former smokers who stopped smoking \<6 months (including all forms of tobacco, e-cigarettes \[vaping\], and marijuana)~* Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)~* Historical or current evidence of a clinically significant disease~* Cancer not in complete remission for at least 5 years~* Hospitalized for psychiatric disorder or attempted suicide within 1 year~* Unable to abstain from protocol-defined prohibited medications during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- • AS MDI 90 µg (Type: EXPERIMENTAL): (2 actuations of 45 µg/actuation)
- • AS MDI 180 µg (Type: EXPERIMENTAL): (2 actuations of 90 µg/actuation)
- • Placebo MDI (Type: PLACEBO_COMPARATOR): (2 actuations)
- • Proventil 90 µg (Type: ACTIVE_COMPARATOR): (1 actuation of 90 µg/actuation)
- • Proventil 180 µg (Type: ACTIVE_COMPARATOR): (2 actuations of 90 µg/actuation)

Based on this trial design, predict the completion outcome and termination type (if applicable).